27389 Rapid and sustained improvement in itch in children aged 6–11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB140
Author(s):  
Amy S. Paller ◽  
Elaine C. Siegfried ◽  
Gil Yosipovitch ◽  
Jonathan I. Silverberg ◽  
Jashin J. Wu ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Phase 3 ◽  
Sustained Improvement

27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

2021 ◽  
Vol 85 (3) ◽  
pp. AB129
Author(s):  
Emma Guttman-Yassky ◽  
Alan D. Irvine ◽  
Jonathan I. Silverberg ◽  
Kim A. Papp ◽  
Amy S. Paller ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Safety Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 3

scholarly journals Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

2018 ◽  
Vol 141 (2) ◽  
pp. AB132
Author(s):  
Mette Deleuran ◽  
Emma Guttman-Yassky ◽  
Kulli Kingo ◽  
Neil M.H. Graham ◽  
Gianluca Pirozzi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pooled Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 3

scholarly journals Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

2018 ◽  
Vol 141 (2) ◽  
pp. AB131
Author(s):  
Eric L. Simpson ◽  
Jean-Philippe Lacour ◽  
Jonathan I. Silverberg ◽  
Margitta Worm ◽  
Andreas Wollenberg ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Food Allergy ◽  
Pooled Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document